BIOMAT Database Logo BIOMAT Database Logo

A comparison of the efficacy and tolerability of enalapril and sustained-release diltiazem in mild to moderate essential hypertension. 1990

M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Division of Nephrology, University of Maryland Hospital, Baltimore.

The subjects of this multicenter study were 159 patients aged 21 to 76 years with mild to moderate uncomplicated essential hypertension. The patients were randomly assigned to receive up to 40 mg of enalapril daily or 360 mg of sustained-release diltiazem daily for a titration period of eight weeks and then maintenance doses for four weeks. The treatment goal was a supine diastolic blood pressure of less than 90 mmHg or a fall of at least 10 mmHg from baseline. During titration, 62% of the enalapril-treated patients and 51% of the diltiazem-treated patients reached the treatment goal after two weeks, 82% and 74% after four weeks, 87% and 84% after six weeks, and 92% and 87% after eight weeks. During the maintenance period, 85% of the enalapril-treated and 87% of the diltiazem-treated patients maintained the goal blood pressure. Treatment side effects were reported by 21% of the enalapril-treated patients and 29% of the diltiazem-treated patients; treatment was discontinued in two patients from each group because of side effects. It is concluded that both drugs were generally well tolerated and effective in the treatment of adult mild to moderate essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension.
January 1990, Clinical therapeutics,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
[Comparison of the efficacy and tolerability of sustained-release verapamil and captopril in mild to moderate essential arterial hypertension].
October 1991, Annales de cardiologie et d'angeiologie,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension.
May 2011, Indian journal of pharmacology,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension.
June 2010, Indian journal of pharmacology,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Comparison of hydrochlorothiazide and sustained-release diltiazem for mild-to-moderate systemic hypertension.
March 1987, The American journal of cardiology,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
A multicentre study to compare the therapeutic efficacy of sustained-release diltiazem and enalapril in the treatment of patients with mild to moderate hypertension.
January 1994, The British journal of clinical practice,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension.
January 2002, Blood pressure,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
January 1997, Journal of hypertension,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Tolerability of enalapril in mild to moderate hypertension.
July 1995, The Journal of the Association of Physicians of India,
M R Weir, and R Haynie, and V Vertes, and R Pinson, and B W Kong, and P Jenkins, and P T Lavin
Comparative study on monotherapy with sustained-release diltiazem 300 mg and enalapril 20 mg in mild to moderate arterial hypertension.
January 1990, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!